ABSTRACT. Treatment of nonhuman primate fetuses with epidermal growth factor (EGF) results in histologic and biochemical maturation of their lungs. To determine whether these effects improve lung function postnatally, we studied premature rhesus infants delivered at 78% of gestation after in utero treatment with EGF (n = 5) or placebo ( n = 5). Indices of lung function during the 4 d of postnatal care included fractional concentration of inspired oxygen, peak inspiratory pressure, ventilator rate, mean airway pressure, arterial to alveolar oxygen tension ratio, and ventilation index. Statistically significant differences were noted in the time courses of these variables between EGF-and placebo-treated infants. The direction of the differences indicated that the EGF-treated infants had less severe lung disease. Surfactant apoprotein A concentration and lecithin to sphingomyelin ratio were both significantly higher in the amniotic fluid of the EGF-treated group, indicating advanced biochemical maturation in this group of animals. Whereas birth weight was not affected by EGF exposure, adrenal and gut weights, standardized for body weight, were increased significantly. Histologic studies showed advanced cellular maturation with increased parenchymal airspace and decreased parenchymal tissue space in the EGF-treated group compared with the control group. We conclude that prenatal exposure to EGF stimulates biochemical and histologic maturation of the lung and markedly attenuates the clinical severity of respiratory disease in this model of simian respiratory distress syndrome. (Pediatr Res 35: 30-36, 1994) 
ABSTRACT. Treatment of nonhuman primate fetuses with epidermal growth factor (EGF) results in histologic and biochemical maturation of their lungs. To determine whether these effects improve lung function postnatally, we studied premature rhesus infants delivered at 78% of gestation after in utero treatment with EGF (n = 5) or placebo ( n = 5). Indices of lung function during the 4 d of postnatal care included fractional concentration of inspired oxygen, peak inspiratory pressure, ventilator rate, mean airway pressure, arterial to alveolar oxygen tension ratio, and ventilation index. Statistically significant differences were noted in the time courses of these variables between EGF-and placebo-treated infants. The direction of the differences indicated that the EGF-treated infants had less severe lung disease. Surfactant apoprotein A concentration and lecithin to sphingomyelin ratio were both significantly higher in the amniotic fluid of the EGF-treated group, indicating advanced biochemical maturation in this group of animals. Whereas birth weight was not affected by EGF exposure, adrenal and gut weights, standardized for body weight, were increased significantly. Histologic studies showed advanced cellular maturation with increased parenchymal airspace and decreased parenchymal tissue space in the EGF-treated group compared with the control group. We conclude that prenatal exposure to EGF stimulates biochemical and histologic maturation of the lung and markedly attenuates the clinical severity of respiratory disease in this model of simian respiratory distress syndrome. (1) (2) (3) (4) (5) . EGF induces increased synthesis and secretion of surfactant and surfactant-associated proteins in these cells. However, there is only limited information as to whether histologic and biochemical maturation induced by EGF confers functional maturation. Fetal administration of EGF to rabbits and lambs increases distensibility of their lungs (6, 7) . Preliminary observations suggest that respiratory distress is less severe in the preterm lambs treated in utero with EGF (7). However, there are no objective data regarding the effects of prenatal exposure to EGF on the time course of respiratory distress in any animal model with surfactant deficiency. Nonhuman primates delivered at 75-80% of term, including rhesus macaques, have been shown to have surfactant deficiency and associated respiratory distress similar to that seen in premature human infants with RDS (8) (9) (10) (11) (12) . Therefore, we elected to study whether prenatal exposure to human recombinant EGF produces functional maturation of the lung sufficient to alter the course of RDS in prematurely delivered rhesus monkeys.
MATERIALS AND METHODS
All procedures used within this study conformed to the requirements of the Animal Welfare Act. The California Regional Primate Research Center is fully accredited by the Association for Accreditation of Laboratory Animal Care and all study protocols were approved before implementation by the Institutiu?.al Animal Use and Care Committee at the University of Califolnia at Davis. Activities related to animal care and surgery/ necropsy were performed according to standard Primate Center operating procedures.
Gestational age and EGF administration. Normally cycling, female Macaca mulatta were bred midcycle with proven fertile males. Pregnancy was confirmed by assay of monkey chorionic gonadotropin or ultrasound on GD 20 + 2 (13, 14) . GD 0 was assigned as the last day of exposure to the male. A total of 1 1 gravid animals whose fetuses had appropriate-for-gestational-age femur length and biparietal diameter at GD 12 1 were selected for the study (14) . Dams received ketamine hydrochloride (10 mg/kg) during fetal injections to immobilize them. Fetal monkeys received recombinant human EGF (1 5) (provided by Chiron Corporation, Emeryville, CA) or saline placebo on GD 12 1, 123, 125, and 127. Because the route of action of EGF on fetal lung development was not known, EGF (40 pg in 1.0 mL of saline) was injected into the amniotic fluid and also into the fetal peritoneal cavity under ultrasound guidance as previously described (16) . Biochemical and histologic maturation of airway epithelial cells was previously demonstrated using this treatment regimen in fetuses of this gestational age (4) . The average EGF dose was 533 pg/kg by each route over the 7-d period as calculated for an approximate average fetal body weight of 300 g. Control fetuses underwent an identical protocol with injections of saline placebo. The treatment status of each animal was assigned by one investigator (L.C.R.), and the personnel providing the neonatal intensive care remained blinded to the assignment until the infant was euthanized.
Neonatal intensive care. Rhesus infants were delivered on GD 128 (78% of gestation) by cesarean section with the dam under general anesthesia. After withdrawing a sample of the amniotic fluid, the fetal head was delivered, the trachea was cannulated with a 2-mm diameter endotracheal tube, and manual positive pressure ventilation was initiated with a self-inflating infant resuscitation device. The remainder of the fetal body was then delivered, the umbilical cord severed, and the infant transferred to a radiant warmer bed in the adjacent intensive care unit. The placenta and membranes were removed after delivery of the infant and their weights obtained.
Mechanical ventilation was continued with a human infant ventilator. The infant was thoroughly dried and ECG leads and oximetry sensors were applied to the extremities for monitoring. Umbilical arterial catheterization was performed with a 3.5 Fr polyvinyl chloride catheter to allow for blood pressure monitoring and continuous fluid and glucose infusion. Vital signs were recorded every 2 h and arterial blood gases were measured as needed but not less than every 6 h. The ventilator management strategy was to maintain the blood gases in the following ranges: Pao2 = 6.6-13.3 kPa (50-100 torr), Paco2 = 4.7-7.3 kPa (35-55 torr), and pH = 7.25-7.45. Ventilator settings and FI02 were adjusted according to blood gas measurements. The end-expiratory pressure was maintained at 0.4 kPa (4 cm H20) and the inspiratory time was maintained at 0.35-0.40 s for the duration of the study. Blood chemistries were obtained for each blood gas sample using a whole-blood analyzer. Urine and blood were periodically tested for glucose. Body weight was obtained daily. Fluid infusion rates and electrolyte composition were adjusted in a manner similar to that described for human infants (17) . Enteral feeding with 2 mL of human infant formula by gavage tube every 3 h began at 24 h of age and increased by 0.5 mL every 12 h as tolerated to a maximum of 5 mL per feeding. Replacement blood transfusion was performed with freshly drawn uncrossmatched adult rhesus blood each time a total of 3 mL of an infant's blood had been drawn for blood tests. Tracheal extubation was not attempted when low ventilator settings were achieved to avoid introducing additional confounding variables.
Lung function. Lung function was assessed by serial analysis of blood gases, FI02, and ventilator settings of PIP, positive endexpiratory pressure (PEEP), and Rate. Three derived variables, MAP, a/A 02, and VI were determined according to the following equations:
where I, is inspiratory time, E, is expiratory time, Patm is atmospheric pressure, and P H~O is the vapor pressure of water. In addition, daily pressure-volume loops were recorded during muscular paralysis induced with parenteral vecuronium, 0.03 mg/kg, at fixed PIP of 15, 30, and 45 cm H20 as described by Caeton et al. (18) . Flow was measured with a size 00 Fleisch pneumotachograph interposed between the ventilator and the tracheal tube connected with a Statham PM197 differential pressure transducer (Gould Statham, Oxnard, CA). Airway pressure was measured by a Hewlett-Packard 1230 pressure transducer (Hewlett-Packard Co., Palo Alto, CA). These signals were fed to respective Hewlett-Packard 17403A amplifiers, and the analog signals were digitized by a computer so that the pressurevolume loops could be displayed and total respiratory compliance estimated ( 18) .
At 90-96 h after delivery, the animals were euthanized with an overdose of pentobarbital and the lungs removed, trimmed of other mediastinal tissues, weighed, and prepared for biochemical and histologic studies. Total body weight, lung weight, and other organ weights were obtained at necropsy. The gut weight included the stomach, small intestine, cecum, and large intestine weights.
Histologic and morphometric measurements. After weighing, the lungs were separated at the canna. The right cranial lobe was cannulated and fixed by airway perfusion at 30 cm of fixative pressure using glutaraldehyde-paraformaldehyde in 0.2 M cacodylate buffer (adjusted to 330 mosmol and pH 7.4). The fixed volume of this lobe was measured by fluid displacement. Specific tissue areas, including airway levels and parenchyma, were selected by microdissection and processed for embedding in Araldite 502 (Electron Microscopy Sciences, Washington, PA). Volume densities of parenchymal air space and parenchymal tissue, alveolar size (mean linear intercept) and alveolar surface area (surface to volume ratio) were estimated by point and intercept counting of 1-pm sections using a light microscope and a graticule containing a Weibel 42-multipurpose test grid (x250 magnification) and by applying standard stereologic formulas. These measurements were performed only on lungs (four animals in each group) where sections of bronchioles were free of artifactual enfoldings as determined by light microscopy. A minimum of five parenchymal fields were selected from various regions of the right cranial lobe of each animal for evaluation.
Biochemical measurements. Amniotic fluid, obtained at the time of delivery, was centrifuged and frozen at -20°C for later analysis of surfactant-associated protein A and surfactant lipid profiles by previously reported biochemical techniques (19, 20) .
Data analysis. The time courses for PIP, Rate, FI02, MAP, a/A 0 2 ratio, and VI were compared by determining the areas under the respective curves for each animal between 1 and 90 h and comparing the group means using the t test (2 1). The mean values for these variables were also compared at 24,48, 72, and 90 h using this test. The mean values for the categorical variables determined for the EGF-treated animals were compared with those for the saline-injected control animals using the t test for group means. No value was used in more than one comparison. A p value less than 0.05 for a two-tailed comparison was considered statistically significant. Values of variables to be compared are given as means f SEM.
RESULTS
Dams were of similar mean body weights (7.2 f 1.0 and 6.1 + 1.5 kg for the control and EGF groups, respectively). One control infant died at 20 h of age from severe RDS complicated by a pneumothorax. Data collected from this animal were omitted from the comparisons to be presented. Two additional animals in the control group developed pulmonary air leaks that required chest tube drainage and both survived. Thus, five EGFtreated and five placebo-treated animals completed the entire study. There were three females and two males in each group.
The time courses for the blood gas measurements of Pao2, Paco2, and pH for the EGF and control groups are presented in Figure 1 . These data suggest that the control group animals were more difficult to maintain in the desired ranges of these variables Time, hours because their mean Pao2 were slightly lower and their mean Paco2 were slightly higher than those of the EGF-treated group. Furthermore, during the first 24 h, we were not uniformly successful in meeting our goals for C02 management for infants in the saline-treated control group. The blood gas variables were not compared statistically because we actively intervened to maintain them in predetermined ranges.
The time course and severity of the lung disease in the EGF and control groups are compared in Figures 2 and 3 . Figure 2 compares the time courses of the supplemental oxygen requirement (FI02) and the ventilator settings of PIP and Rate. The animals were significantly different from those of the control group with p values of 0.0003, 0.002, and 0.0004 for MAP, a/A 0 2 ratio, and VI, respectively. These data show that the EGFtreated animals required less ventilator support (PIP, Rate, MAP, and VI) and less supplemental oxygen (FI02 and a/A O2 ratio) than the control animals. Thus, it was concluded that the EGFtreated animals had a less severe respiratory disorder according to these indices. In addition, the time course of the respiratory disease was shorter for the EGF-treated animals, as evidenced by their achieving low stable values for supplemental oxygen and ventilatory support by 42 h of age, whereas the control animals had not achieved this level of improvement at 90 h of age. The ventilator rate for the EGF-treated animals was significantly lower than that for the control group at 24, 48, 72, and 90 h. At 72 h, the FIO2 and VI ceased to be significantly different for the two groups. At 90 h, the remaining variables of PIP, MAP, and a/A O2 ratio ceased to be statistically different as the placebotreated animals' lung disease spontaneously resolved. At the termination of the study, the mean NO2, PIP, and Rate for the EGF-treated group were 0.24 f 0.04, 1.80 f 0. The total lung compliance values for the control and EGFtreated groups at 24 and 90 h of age are shown in Table I . There were no significant differences within or between groups at these times or at the different inspiratory pressures.
The group mean body weights, organ weights, and organ weight to body weight ratios for selected organs are presented in Tables 2 and 3 . No significant differences were detected between the two groups for birth weight, placenta to birth body weight ratio, or necropsy body weight. However, the adrenal to necropsy body weight and the gut weight to necropsy body weight were greater for the EGF-treated group ( p = 0.036 and 0.002, respectively). The mean wet lung weight to necropsy body weight was slightly less for the EGF-treated group of animals, but the difference did not reach statistical significance ( p = 0.078). Liver, kidney, and brain weights were unaffected by treatment with EGF. Parenthetically, there were no differences between the two groups for spleen, thyroid, and eye weights (data not shown). Our results show that treatment of preterm rhesus monkey fetuses with EGF for 1 wk before delivery markedly attentuates a*:
' K the time course and severity of their postnatal respiratory distress.
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hypotension was induced on the 4th d of the EGF infusion and the lambs were delivered the next day and mechanically ventilated for up to 6 h. The control twins were reported to have more severe respiratory distress than the EGF-treated twins based on clinical findings. However, no blood gas or ventilator data were presented. In addition, the EGF-treated animals had histologic evidence of lung maturation as well as epithelial hyperplasia of the conducting airways, which was considered an effect of EGF f r administration. In a smaller number of lamb fetuses of comparable gestational age infused with EGF for 3% days (approximately 8 ccg/kg/d), Schellenberg et al. (22) did not observe any effects of EGF on lung distensibility or epithelial hyperplasia. However, Haigh et al. (3) injected 8 pg of human EGF into the peritoneum of fetal rabbits on d 25 of gestation and found increased surfactant phospholipids in tracheal lavage specimens obtained at delivery 3 d later. In a related study, Kennedy et al. (23) showed that infusion of 64 pg/kg EGF to fetal sheep at 132 d of gestation decreased lung liquid production by a mechanism that was not blocked by j3-adrenergic antagonists. Decreased production of lung liquid is normally seen in preparation for birth (24) .
Fie. 4. Light microsco~ic comparison of lung parenchyma in rhesus
We did not find a difference in lung compliance between EGFmonkey infants after 4 d of mechanical ventilation after in utero treat-treated and control animals. Our results are similar, in this regard, ment with either EGF (A) or saline (B). Magnification = 210x. In EGF-to those obtained from surfactant-treated human infants with treated infants, the alveolar air spaces were larger and more uniform in RDS compared with untreated controls (25, 26) . These failures size than in the saline-treated control infants.
to detect compliance differences may be due to collecting measHistologic appearance of the parenchymal tissue differed between EGF and control animals (Fig. 4) . The lungs of the control Table 4 . Comparison of proportion of parenchyma air space and animals appeared to have smaller air spaces with larger inter& tissue space, air space size as the mean linear intercept (MLI). veolar septa. The epithelium lining the air space side of the septa and air space surface to vohme ratio in lungs of EGF-treated was thicker, more cuboidal, and appeared to be composed of (n = 4) and control (n = 4) rhesus infant? more cells, and there was a wide range of septa1 thickness. In urements on ventilator breaths when there is lung overdistention as well as the inabilitv to reduce lung stiffness bv these thera~ies. Our findings of inireased surfacgnt apoprotdin A and sukactant vhosvholipids in the amniotic fluid of the EGF-treated monkeys are consistent with a previous report from our center. Plopper et al. (4) observed cytodifferentiation of alveolar type I1 cells in the lungs of animals delivered at 128 d of gestation after fetal EGF exposure similar to that described in this report but killed at birth. There was marked loss of glycogen from these cells and a decrease in the number of type I1 cells without lamellar bodies. Their data suggest that increased surfactant production and secretion may be responsible for the functional maturation of lung that we observed after EGF exposure. In addition, a previous report with this rhesus model has shown maturation of the tracheal mucous secretory cells after fetal EGF exposure (27) . However, the proliferation of basal and intermediate cells resulting in epithelial sloughs that Stahlman et al. (28) observed in the larger airways in fetal lambs exposed to EGF were not seen. Thus, there may be species differences in the pulmonary responses to EGF, particularly if there are critical times during gestation for EGF to produce its pulmonary effects or differences in the availability of vitamin A at such times.
We elected to provide broad exposure to EGF in this series of experiments, which were run in parallel to those described in the study by Plopper et al. (4) , to determine whether any response to EGF would be detectable. We considered that intra~eritoneal EGF could reach the lungs by the systemic rout6 whereas intraamniotic EGF could be inhaled during fetal breathing and reach the lung directly. In addition, EGF may have been absorbed directly into the fetal circulation after intraamniotic injection by the recently described intramembranous route (29, 30) . This discovery has important implications for the pharmacologic treatment of the fetus (30) . Of course, EGF could be swallowed and could have produced the significant increase in gut weight in the EGF-treated group. ~xperiments are in progress to determine the dose of EGF. the duration of exDosure. and which route of exposure produced the observed efficts on' lung and gut maturation.
In vitro exposure to EGF has been reported to produce biochemical and histologic maturation in lung tissue of several species (1, 3). Gross et al. (1) showed a dose-dependent effect of EGF exposure on the rate of choline incorporation into phosphatidylcholine in explants of fetal rat lungs. Similarly, Haigh et al. (3) showed that human EGF enhanced the incorporation of radiolabeled choline into phosphatidylcholine in cultured fetal rabbit alveolar type I1 cells. Whitsett et al. (2) demonstrated that EGF exposure for 2 d induced the production of surfactant apoprotein A in explants of human lung tissue obtained at 15-24 wk of gestation. Preliminary work by Nielsen (3 1) suggested that the effect of EGF on epithelial cells might be indirect and mediated by interaction with fibroblasts. This was supported by the finding of Sen and Cake (32) that a fibroblast-derived factor stimulated EGF-induced choline incorporation into phosphatidylcholine by pure alveolar type I1 cells from rats. Cortisol was not required for this action, but the action was similar to findings of others on the mechanism of cortisol stimulation of type I1 cells (33, 34) . In contrast, both Scott (35) and Raaberg et al. (36) were able to demonstrate direct EGF stimulation of type I1 cells without other cells or cell-conditioned media. The latter group also demonstrated EGF production within type I1 cells and suggested an autocrine function for this peptide growth factor. Thus, although the mechanism of action of EGF is incompletely understood, it does not appear that the effects of EGF on alveolar type I1 cells are mediated by cortisol.
Receptors for EGF and its fetal form, transforming growth factor-a, are widely distributed in fetal tissues including the lung and specifically the alveolar type I1 cells (37) (38) (39) . This suggests that EGF/transforming growth factor-a plays a role in fetal development. In addition to the pulmonary maturational effects discussed above, we observed a trend toward decreased lung weight with EGF treatment. A similar decrease has been observed with glucocorticoid stimulation of fetal lung maturity (34) . However, we observed an increase in adrenal and gut weights, whereas total body weight and placental weight were unaffected by EGF treatment. EGF has been reported to have similar effects on fetal sheep in addition to marked effects on their skin and wool (40) . Interestingly, body growth of rats and mice can be either stimulated or retarded by EGF depending on their stage of develop ment when EGF is administered (41, 42) , and suppression of IGF has been observed during EGF-induced growth retardation (43) . Our results on brain weights in fetal monkeys are consistent with an apparent lack of EGF effect on brain growth (44) . Our results after 1 wk of EGF exposure do not allow speculation on whether longer exposure of fetal macaques would affect ponderal growth or lung growth.
Biochemical, histologic, and clinical studies have established that rhesus infants delivered near 80% of term can provide useful models of the RDS (8-10). However, previous studies were terminated 2-24 h after birth (10) (11) (12) and the complete time course of respiratory distress in this species had not been established before the studies described herein. The clinical findings for our control animals confirm that rhesus infants delivered at 78% of gestation provide an acceptable primate model for the entire acute course of RDS when intensive care support is provided.
RDS continues to be a major cause of neonatal mortality and chronic lung disease continues to occur in survivors in spite of advances in treatment, including prenatal treatment with glucocorticoids and postnatal treatment with exogenous surfactant. Both surfactant deficiency and structural immaturity are important factors in determining these outcomes (45, 46) . In our study, rhesus infants treated with EGF had advancement of both biochemical and structural development of their lungs and would be predicted to have both lower mortality and a lower incidence of BPD than the control infants. Although BPD has been described in nonhuman primate infants after RDS (47), our experiments were not designed to detect an effect on BPD. However, our findings do have implications for the prevention of RDS in human premature infants and may be even more significant if a role for reducing the incidence of BPD is confirmed.
